The ongoing battle between pharmaceutical manufacturers and 340B covered entities has entered a new and potentially consequential phase. Eli Lilly recently notified federal regulators that it intends to withhold 340B pricing from certain covered entities that fail to provide claims-level data within five business days of a request. According to Lilly, the data is necessary to identify potential duplicate discounts and diversion concerns. Hospitals and health systems, however, view the policy as a significant expansion of manufacturer oversight and a direct threat to the continued viability of many 340B programs.
Operational Challenges of Claims-Level Data Reporting
For many hospital systems, compliance with Lilly’s mandate is far easier said than done. While some covered entities have implemented processes to collect and report claims-level data associated with retail pharmacy dispensing, many have not. Even among sophisticated health systems, the challenge becomes substantially more complicated because Lilly’s data request extends beyond traditional outpatient pharmacy claims and includes drugs administered in hospital outpatient departments (HOPDs), infusion centers, and other clinical settings. These services often operate on entirely different electronic health record, billing, and pharmacy platforms, making the collection, validation, and transmission of the requested data a costly and burdensome undertaking.
A New Front in the 340B Battle
Beyond the operational burden, many covered entities are concerned about the precedent Lilly’s policy may establish. Hospitals have spent years pushing back against manufacturer-imposed contract pharmacy restrictions, rebate models, and other efforts to limit access to 340B pricing. Lilly’s latest action represents a new front in that broader conflict, one that shifts the focus from where drugs are dispensed to what data manufacturers can require as a condition of receiving statutory discounts.
While Lilly is the first major manufacturer to take this approach, there is concern that other manufacturers will follow suit, especially if Lilly’s policy remains unchallenged. As hospitals evaluate their response, many are considering not only the immediate impact of Lilly’s demands but also the long-term implications for the 340B program as a whole.
Potential Legal and Regulatory Responses
Several covered entities and other groups have already begun to explore legal options. In addition to filing formal complaints with HRSA, covered entities may also pursue the 340B Administrative Dispute Resolution (ADR) process to challenge Lilly’s latest efforts.
As manufacturers continue testing new strategies to limit or condition access to 340B pricing, hospitals and health systems should carefully assess their operational capabilities, quantify their financial exposure, and evaluate available legal and regulatory options. What began as a dispute over contract pharmacies is rapidly evolving into a broader battle over data, oversight, and the future scope of the 340B program itself.
How Frier Levitt Can Help
Frier Levitt’s 340B and Pharmacy Practice Groups continue to monitor developments related to manufacturer data demands, contract pharmacy restrictions, rebate models, and other threats affecting 340B covered entities. Hospitals and health systems with questions regarding Lilly’s policy or their compliance obligations should contact Frier Levitt today.
